Sleep Wake Disorders
0
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Vanda PharmaceuticalsWASHINGTON, DC
2 programsTasimelteonPHASE_31 trial
TasimelteonPHASE_31 trial
Active Trials
Nitto BioPharmaCA - San Diego
1 programPSG Validation Study of Zensorium Biosensing Wearable DeviceN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Vanda PharmaceuticalsTasimelteon
Vanda PharmaceuticalsTasimelteon
Nitto BioPharmaPSG Validation Study of Zensorium Biosensing Wearable Device
Clinical Trials (3)
Total enrollment: 198 patients across 3 trials
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
Start: Oct 2024Est. completion: Jun 202560 patients
Phase 3Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
Start: Dec 2020Est. completion: Jun 202670 patients
Phase 3Recruiting
PSG Validation Study of Zensorium Biosensing Wearable Device
Start: Nov 2019Est. completion: Oct 202068 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 198 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.